Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure-Reference-Cited by-同舟云学术

Sacubitril/Valsartan in Patients Hospitalized With Decompensated Heart Failure

Published:2024-03 Issue:12 Volume:83 Page:1123-1132
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Morrow David A.,Velazquez Eric J.,Desai Akshay S.,DeVore Adam D.,Lepage Serge,Park Jeong-Gun,Sharma Kavita,Solomon Scott D.,Starling Randall C.^ORCID,Ward Jonathan H.,Williamson Kristin M.,Zieroth Shelley,Hernandez Adrian F.,Mentz Robert J.,Braunwald Eugene

Funder

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Reference14 articles.

1. Angiotensin-neprilysin inhibition versus enalapril in heart failure;McMurray;N Engl J Med,2014

2. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction;Solomon;N Engl J Med,2019

3. Rationale, design and baseline characteristics of the PARAGLIDE-HF trial: sacubitril/valsartan vs valsartan in HFmrEF and HFpEF with a worsening heart failure event;Mentz;J Card Fail,2023

4. Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure;Mentz;J Am Coll Cardiol,2023

5. Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial;Velazquez;Am Heart J,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In-hospital initiation of angiotensin receptor–neprilysin inhibition in acute heart failure: the PREMIER trial;European Heart Journal;2024-08-31

2. Disposition Decisions;JACC: Advances;2024-07

3. Pooling the NT-proBNP Benefits of ARNI;Journal of the American College of Cardiology;2024-03